CIK 0001427570
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
Vyome Holdings, Inc
Sign in to watch- Ticker
- HIND
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 949-429-6680
- Business address
- 1001 CALLE AMANECER, SAN CLEMENTE, CA, 92673
- Former names
- ReShape Lifesciences Inc., OBALON THERAPEUTICS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2020-01-24 | Brister Mark Chief Technology Officer | Grant or award · Restricted Stock Units | +110,281 | 110,281 | ||
| 2019-10-25 | Brister Mark Chief Technology Officer | Grant or award · Stock Option (Right to Buy) | +13,000 | 13,000 | ||
| 2019-08-06 | Brister Mark Chief Technology Officer | Purchase | +5,000 | $4.00 | $20K | 38,865 |
| 2019-08-06 | Brister Mark Chief Technology Officer | Purchase · Warrants (Right to Buy) | +3,750 | 3,750 | ||
| 2019-07-23 | Brister Mark Chief Technology Officer | Grant or award · Stock Option (Right to Buy) | +35,000 | 35,000 | ||
| 2019-01-02 | Brister Mark Chief Technology Officer | Grant or award · Stock Option (Right to Buy) | +100,000 | 100,000 | ||
| 2018-08-23 | Brister Mark Chief Technology Officer | Grant or award | +107,142 | $1.82 | $195K | 338,634 |
| 2018-04-30 | Brister Mark Chief Technology Officer | Grant or award | +2,622 | $3.27 | $9K | 166,492 |
| 2018-01-02 | Brister Mark Chief Technology Officer | Grant or award | +65,000 | 65,000 | ||
| 2017-10-31 | Brister Mark Chief Technology Officer | Grant or award | +1,860 | $7.17 | $13K | 163,870 |
| 2017-04-30 | Brister Mark VP of Research and Development | Grant or award | +1,550 | $9.03 | $14K | 162,010 |
| 2016-11-09 | Brister Mark VP of Research and Development | Grant or award · Stock Option (right to buy) | +90,000 | 90,000 |
Page 1 of 1 · 12 trades